Glycan Sequence‐Dependent Nod2 Activation Investigated by Using a Chemically Synthesized Bacterial Peptidoglycan Fragment Library by Wang, Ning et al.
DOI: 10.1002/cbic.201200655
Glycan Sequence-Dependent Nod2 Activation Investigated
by Using a Chemically Synthesized Bacterial Peptidoglycan
Fragment Library
Ning Wang,[a] Cheng-yuan Huang,[a] Mizuho Hasegawa,[b] Naohiro Inohara,[b]
Yukari Fujimoto,*[a] and Koichi Fukase*[a]
Introduction
Innate immune receptors recognize a variety of microbial com-
ponents, known as microbe-associated molecular patterns
(MAMPs) or pathogen-associated molecular patterns (PAMPs),
to activate the immune system. A variety of innate immune
receptors, also known as pattern-recognition receptors (PRRs),
have been identified, including Toll-like receptors (TLRs), Nod-
like receptors (NLRs), RIG-like receptor (RLR) and C-type lectin
receptor (CLR). Nucleotide oligomerization domain-containing
proteins 1 and 2 (Nod1, Nod2),[1, 2] which are founding mem-
bers of the NLR family, recognize peptidoglycan (PGN).[3–5] PGN
contains long glycan chains consisting of alternating N-acetyl-
glucosamine (GlcNAc) and N-muramic acid (MurNAc) linked by
a b(1!4) bond. The glycans are connected to one another
through a peptide linkage at the carboxylic acid of MurNAc,
outside the plasma membrane. In most bacteria, l-Ala-g-d-Glu
or l-Ala-g-d-GluNH2 (l-Ala-g-d-isoGln) is connected to MurNAc,
and the third amino acid connecting to the Glu (or GluNH2) is
usually a diaminocarboxylic acid: l-Lys in many Gram-positive
bacteria or meso-diaminopimelic acid in most Gram-negative
bacteria or some Gram-positive bacteria. Our group has syn-
thesized a variety of PGN fragment structures in an effort to
search for structures recognized by the PGN receptors.[6] This
work has revealed the minimum ligand recognition structures
of Nod1 and Nod2.[1, 3] Because Nod1 and Nod2 are cytosolic
proteins and both proteins prefer smaller ligands rather than
PGN itself,[1–4] enzymatic digestion of PGN, followed by ligand
transport appears to be critical for Nod1 and Nod2 recognition.
NOD2 mutations are associated with a susceptibility to inflam-
matory diseases, including early-onset sarcoidosis (EOS), Blau
syndrome (BS), and Crohn’s disease (CD).[7–9]
Our previous studies revealed that Nod2 recognizes a mur-
amyl dipeptide (MDP, MurNAc-l-Ala-g-d-isoGln) as the mini-
mum ligand structure and also recognizes peptidoglycan frag-
ments containing MDP. MDP showed the most potent Nod2-
stimulating activity, and the activity decreased as the glycan
and peptide chain lengths increased.[6, 10–13] In these studies, we
synthesized tetrasaccharide and octasaccharide fragments that
contained the GlcNAc-MurNAc unit. In host organisms, sequen-
ces containing the GlcNAc-MurNAc unit are produced by lyso-
zyme, also known as muramidase, which cleaves b(1!4) link-
ages between N-acetylmuramic acid and N-acetyl-d-glucosa-
mine residues in PGN.
Various PGN fragments are released from bacteria during
bacterial cell lysis. These fragments are produced by bacterial
muramidase and glucosamidase and, therefore, contain two
glycan sequences: repeating units of GlcNAc-MurNAc or
MurNAc-GlcNAc (Figure 1). The disaccharides MurNAc-GlcNAc
and GlcNAc-MurNAc with dipeptides were previously synthe-
sized,[14] but not clear differences in the immunostimulatory ac-
tivities of the compounds were observed. Peptidoglycan frag-
ments with more than two MurNAc-GlcNAc repeating units
have not previously been synthesized; therefore, we investigat-
ed the biological activities of such synthetic fragments by test-
ing their innate immunostimulatory activities through the in-
tercellular receptor, Nod2. This study reports the first synthesis
of tetrasaccharide fragments, particularly compounds contain-
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Nucleotide oligomerization domain-containing protein 2
(Nod2), an innate immune receptor, recognizes bacterial cell-
wall peptidoglycan (PGN), the minimum ligand of which is
muramyl dipeptide (MDP). Enzymatic digestion of PGN appears
to be important for Nod2 recognition. PGN is degraded by
muramidase or glucosamidase through a process that produ-
ces two types of glycan sequence; glycans containing
GlcNAcb(1!4)MurNAc or MurNAcb(1!4)GlcNAc. In this
report, a range of disaccharide or tetrasaccharide fragments of
each sequence were chemically synthesized, and their activities
in stimulating human Nod2 (hNod2) were investigated. The re-
sults reveal that hNod2 recognitions is dependent on the
glycan sequence, as demonstrated by comparing the activities
of glycans with the same peptide moieties. (MurNAcb(1!
4)GlcNAc)2-containing structures exhibited stronger activity
than those containing (GlcNAcb(1!4)MurNAc)2. The results
suggest that differences in the enzymatic degradation process
affect the host’s immunomodulation process.
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ing MurNAc-GlcNAc repeating units. The activities of the tetra-
saccharide-containing PGN fragments, as well as the di- and
monosaccharide-containing fragments, were systematically in-
vestigated in human Nod2 (hNod2) for the first time.
Results and Discussion
Synthesis of peptidoglycan fragment library
Syntheses of PGN fragments have been reported previously, in-
cluding by us.[5, 6] In our studies, 2-N-Troc (Troc: 2,2,2-trichloro-
ethoxycarbonyl) protection was used for both the glycosyl
donor and acceptor for the glycosylation of glucosamine
(GlcN) and muramic acid (MurN) in the synthesis of the com-
plex PGN fragments.[10, 11] A high b-selectivity was obtained
with neighboring group participation of the N-Troc group. The
glycosyl acceptor 4 showed a higher reactivity than the N-ace-
tylated acceptors. In our latest study, we applied the same N-
Troc protection strategy. We also examined the leaving groups
in the donors: trichloroacetimidate[10, 15] and N-phenyltrifluoro-
acetimidate.[16] N-phenyltrifluor-
oacetimidate showed good reac-
tivity toward glycosylation at the
4-OH group in the MurNTroc res-
idue, as shown below.
The repeating glycans in com-
pounds 1 a–1 g (Figure 1 B) were
constructed by preparing the
key disaccharide glucosaminyl-
b(1!4)-muramic acid intermedi-
ate 5, as shown in Scheme 1,
based on methods developed
previously in our group.[10, 11] b-
Selective glycosylation with the
N-Troc-muramyl trichloroacetimidate donor 3 of the N-Troc-
glucosaminyl acceptor 4 was carried out in the presence of
catalytic amounts of trimethylsilyl trifluoromethanesulfonate
(TMSOTf) as the activator to afford the disaccharide 5 in high
yield (84 %).
The disaccharide analogues were then synthesized from 5,
as illustrated in Scheme 2. Cleavage of the Troc groups of 5
with Zn/Cu in AcOH and subsequent acetylation with Ac2O
gave compound 6. The allyl group was isomerized to a vinyl
group by using H2-activated [Ir(cod)(MePh2P)2]PF6 (cod = 1,5-cy-
clooctadiene) to give compound 7, and cleavage of the ethyl
ester with LiOH gave 8. The appropriate peptides were intro-
duced to the liberated carboxylic acid 8 by using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (“water-solu-
ble carbodiimide”, WSCD·HCl), 1-hydroxybenzotriazole (HOBt),
and triethylamine (TEA). The vinyl group was then cleaved
with iodine and H2O, and hydrogenation with Pd(OH)2 success-
fully gave the disaccharide fragments 1 a, 1 c, and 1 e.
Tetrasaccharide 12 was then synthesized by using 5 as
a common synthetic intermediate for both the glycosyl donor
Scheme 1. Synthesis of the key disaccharide intermediate 5. a) TMSOTf, CH2Cl2, 15 8C, 4  molecular sieves,
20 min, 84 %.
Figure 1. A) Cell surface of a Gram-positive bacterium and schematic diagram of the enzymatic cleavage of the cell-wall component, peptidoglycan. B) A PGN
fragment library containing two types of glycan sequence.
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and acceptor (Scheme 3). The disaccharide donors 10 a and
10 b were prepared through cleavage of the allyl glycoside
and subsequent conversion to their imidate forms (10 a : tri-
chloroacetimidate, 10 b : N-phenyltrifluoroacetimidate). Regio-
selective reductive ring opening of the 4’,6’-O-benzylidene of 5
was carried out by using BH3·Me3N and BF3·Et2O in CH3CN
[17] to
afford the disaccharide glycosyl acceptor 11 with a free 4-hy-
droxy group in 83 % yield. For the preparation of the tetrasac-
charide 12, the trichloroacetimidate 10 a was first used as the
glycosyl donor in a coupling reaction with the glycosyl accept-
or 11;[11] however, glycosylation between 10 a and 11 in the
presence of TMSOTf as a Lewis acid gave the desired tetrasac-
charide 12 only in 16 % yield, with a 62 % recovery of 11. An in-
crease in the reaction temperature or changes in the equiva-
lents of reactants did not improve the yield. Possible reasons
for the low yield include: 1) The 4-OH group of the disacchar-
ide acceptor 11 has a low reactivity due to steric hindrance
from the 3-O-lactyl moiety in the muramic acid residue; 2) tri-
chloroacetimidate 10 a is highly reactive, but the activated cat-
ionic intermediate decomposes prior to the desired glycosyla-
tion because attack of 11 on the intermediate is sterically en-
cumbered.
We then used the N-phenyltrifluoroacetimidate[16] 10 b as
the glycosyl donor. Generally, glycosyl N-phenyltrifluoroacetimi-
dates are also highly reactive but show better stabilities than
the corresponding trichloroacetimidates. The formation of N-
glycosyl trifluoroacetamides as by-products is suppressed be-
cause the N-phenyl group of the eliminated N-phenyltrifluoroa-
cetamide prevents the undesirable attack of the amide on the
cationic intermediates. Glycosylation by N-phenyltrifluoroaceti-
midate 10 b was promoted by increasing the equivalent of ac-
ceptor 11 (donor/acceptor ratio 1:1.5). The glycosylation yield
when using acceptor 11 improved dramatically to 61 % of tet-
rasaccharide 12.
Removal of the N-Troc groups from the amino groups at the
2-positions of 12, N-acetylation of the liberated amino groups,
and saponification of the ethyl esters produced the dicarboxyl-
ic acid 13 with a tetrasaccharide MGMG (MurNAc-GlcNAc)2
sequence. The glycan backbone 13 was then coupled to di-,
tri-, tetra-, and pentapeptides by using condensation reagents
in DMF. Condensation of 13 with HCl·l-Ala-d-isoGln(OBn) and
HCl·l-Ala-d-isoGln-l-Lys(Z)(OBn) was effected by using WSCD,
HOBt, and triethylamine to give the protected tetrasaccharide
containing two units of dipeptide 14 in 82 % yield and the tri-
peptide 15 in 53 % yield. Condensation of the longer peptide
was achieved by using O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tet-
ramethyluronium hexafluorophosphate (HATU) as a coupling
reagent along with triethylamine to obtain higher yields ; this
resulted in a tetrasaccharide with tetrapeptides, 16, in 81 %
yield and a tetrasaccharide with pentapeptides, 17, in 71 %
yield. All benzyl and benzylidene groups were then removed
to obtain PGN fragments of tetrasaccharides having di-, tri-,
Scheme 2. Synthesis of the PGN disaccharide fragments 1 a, 1 c, and 1 e. a) Zn/Cu, AcOH, 30 min; b) Ac2O/Py, 1 h, 74 % (2 steps); c) [Ir(cod)H(MePh2P)2]PF6;
THF, 1.5 h, 68 %; d) LiOH, dioxane/THF/H2O (2:4:1), quant; e) 9 a, 9 b and 9 c, WSCD·HCl/HOBT/TEA DMF, 72 % (with 9 a), 59 % (with 9 b) or 48 % (with 9 c) ;
f) I2/H2O, 64, 54, 64 %, respectively; g) H2/Pd(OH)2, AcOH, 91 % (1 a), 89 % (1 c), 90 % (1 e).
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tetra-, or pentapeptides (1 b, 1 d, 1 f, or 1 g, respectively). In
order to compare the biological activities of the two kinds of
glycan sequence, PGN fragments with the disaccharide
GlcNAc-MurNAc units, such as a disaccharide with a dipeptide
(2 a) or a tetrasaccharide with di-, tri-, or tetrapeptide (2 b, 2 c,
or 2 d, respectively) as shown in Figure 1, were also synthe-
sized according to the previously reported methods.[11]
Human Nod2 stimulation with PGN fragments in a glycan-
sequence-dependent manner
The hNod2 stimulatory activity of each synthetic PGN fragment
was then evaluated by using hNod2-transfected HEK293T cells,
with NF-kB activation determined by using a luciferase report-
er assay, as described previously.[18] As shown in Figure 2 A, the
synthesized tetrasaccharides containing PGN fragments (1 b,
1 d, 1 f, 1 g, and 2 b–2 d) were compared with the monosac-
Scheme 3. Synthesis of PGN tetrasaccharide fragments. a) [Ir(cod)H-
(MePh2P)2]PF6, THF, 1.5 h; b) I2/H2O, 30 min, 81 %; c) CCl3CN/Cs2CO3, CH2Cl2,
30 min, quant. (10 a) ; d) CF3(NPh)Cl/Na2CO3, acetone, 3 days, 76 % (10 b) ;
e) Me3N BH3/BF3·Et2O, CH3CN, 1 h, 83 %; f) TMSOTf, CH2Cl2, 15 8C, 4  molec-
ular sieves, 40 min, 16 % (from 10 a) or 61 % (from 10 b) ; g) Zn/Cu, AcOH,
3 h, Ac2O/Py, 2 h, 62 %; h) LiOH, quant. ; Condensation: i) WSCD/HOBt/DMF/
TEA, HCl·l-Ala-d-isoGln(OBn) (for 14) or HCl·l-Ala-d-isoGln-l-Lys(Z)(OBn) (for
15) ; j) HATU/DMF/TEA, HCl·l-Ala-d-isoGln-l-Lys(Z)-d-Ala(OBn) (for 16) or
HCl·l-Ala-d-isoGln-l-Lys(Z)-d-Ala-d-Ala(OBn) (for 17) ; k) H2/Pd(OH)2, AcOH.
Figure 2. Stimulation of hNod2 by the synthesized PGN fragments. A) Dose-
dependent hNod2 activation by the chemically synthesized tetrasaccharide
containing PGN fragments, in comparison to a monosaccharide-dipeptide
(MDP). B) hNod2 activation by the chemically synthesized disaccharide- and
tetrasaccharide-containing PGN fragments at concentrations of 1 ng mL1. A
Nod2 activation of 1000 mU is equal to the activation of MDP at 1 ng mL1.
HEK293T cells were transfected with hNOD2, and the indicated amount of
each compound was added to the cells. The ability of each compound to
activate NF-kB was determined by using a luciferase reporter assay.[18]
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charide dipeptide MDP in a dose-dependent manner. In both
glycan sequences, the tetrasaccharide compounds with dipep-
tide (l-Ala-d-isoGln; 1 b and 2 b) exhibited stronger activities
than the same glycan sequence groups with longer peptide
chains. The dependence on peptide length was consistent
with previous results.[11] Interestingly, differences in the glycan
sequence caused significant differences in hNod2 activation,
and the MurNAc-GlcNAc (MG)-containing sequence displayed
more potent activity than the GlcNAc-MurNAc (GM) sequence.
Among the dipeptide-containing fragments, MGMG2 (1 b)
showed stronger activity than GMGM2 (2 b) at concentrations
of 1 and 10 ng mL1. GMGM3 (2 c) and GMGM4 (2 d) exhibited
only very weak activation even at higher concentrations (1000
and 10 000 ng mL1), but MGMG3 (1 d) and MGMG4 (1 f)
showed much stronger hNod2 activation.
Figure 2 B, shows the hNod2 activities of the disaccharides
(1 a, 1 c, and 2 a), and also the tetrasaccharide fragments (1 b,
1 d, 1 f, 1 g, and 2 b–2 d) obtained at concentrations of
1 ng mL1. Among the PGN fragments, the disaccharides with
dipeptides, 1 a and 2 a, showed potent activities comparable
to the activation of the monosaccharide dipeptide, MDP. In
these cases, it was not clear that the differences in glycan se-
quence affected hNod2 activation. Among the tetrasaccharide
fragments, the activity clearly depended on the glycan se-
quence, and compounds with the MGMG sequence exhibited
higher hNod2 activation than those containing the GMGM se-
quence, all other aspects of the peptide structures being the
same. The hNod2 stimulatory abilities of the two types of
glycan sequence differed significantly in the tetrasaccharide
case: MGMG2 (1 b) had an approximately tenfold higher activi-
ty than GMGM2 (2 b) ; MGMG3 (1 d) had an approximately 65-
fold higher activity than GMGM3 (2 c) ; and MGMG4 (1 f) had
an approximately 26-fold higher activity than GMGM4 (2 d).
In this research, we have revealed major differences be-
tween the hNod2 innate immunostimulatory activities of pepti-
doglycan fragments having one of two types of glycan se-
quence. The MGMG (MurNAc-GlcNAc)2 sequences (obtained
through cleavage by N-acetylglucosaminidase) showed much
stronger hNod2 activities than GMGM (GlcNAc-MurNAc)2 se-
quences (cleaved by muramidase, including lysozyme), for a
given peptide structure.
Conclusions
We have described the preparation of various PGN fragments
containing alternating glycan disaccharide or tetrasaccharide
sequences and a series of peptide chains, from di- to penta-
peptides in good overall yields. The sequential glycosylation
method provided an efficient approach to the divergent syn-
thesis of PGN fragment structures with repeating glycan pat-
terns. The chemically synthesized PGN fragments were tested
for their hNod2 stimulatory activities. The results suggest that
hNod2 activation by PGN fragments depends on the circum-
stances under which the PGN glycan is enzymatically cleaved,
that is, by N-acetylglucosaminidase or muramidase. The results
suggest that differences in the bacterial PGN degradation or
construction enzymes (glycan cleaving enzymes or the pepti-
dases) might affect immunomodulation in humans.
Experimental Section
Synthesis of the tetrasaccharide fragments : Compounds and
spectroscopic data not described below are provided in the Sup-
porting Information.
Glycosylation for the preparation of the tetrasaccharide inter-
mediate 12 (from 10 b): TMSOTf (5 mL, 0.03 mmol) was added to
a mixture of the imidate 10 b (135 mg, 0.11 mmol), the acceptor 11
(200 mg, 0.18 mmol), and MS4A 4  molecular sieves in dry CH2Cl2
(20 mL) at 15 8C. After the mixture had been stirred at the same
temperature for 20 min, the reaction was quenched with chilled
sat. aq. NaHCO3 (10 mL), and the mixture was extracted with CHCl3
(50 mL). The organic layer was washed with sat. aq. NaHCO3
(20 mL) and brine (20 mL), dried over Na2SO4, and concentrated in
vacuo. The residue was purified by silica gel chromatography
(30 g, toluene/EtOAc 7:1) to give 12 as a colorless solid (141 mg,
61 %). 1H NMR (CDCl3, 500 MHz): d= 7.45–7.18 (m, 30 H), 5.85–5.82
(m, 2 H), 5.41 (s, 1 H), 5.24–5.12 (m, 3 H), 4.88–4.59 (m, 14 H), 4.50–
4.10 (m, 13 H), 4.02–3.87 (m, 7 H), 3.77 (m, 1 H), 3.67–3.49 (m, 8 H),
3.40–3.38 (m, 3 H), 3.25 (t, J = 10.0 Hz, 1 H), 3.17 (br s, 1 H), 3.06 (d,
J = 10.0 Hz, 1 H), 2.97–2.94 (m, 2 H), 1.38 (d, J = 7.0 Hz, 3 H), 1.29–
1.24 ppm (m, 9 H); 13C NMR (CDCl3, 125 MHz): d= 175.6, 173.9,
155.9, 155.5, 154.3, 154.0, 139.5, 138.9, 138.1, 137.8, 137.6, 137.2,
133.5, 129.5, 129.1, 129.1, 128.6, 128.5, 128.4, 128.4, 128.3, 128.2,
128.1, 127.9, 127.8, 127.6, 127.4, 127.3, 127.1, 125.9, 117.9, 102.8,
101.8, 100.2, 96.6, 96.0, 95.6, 95.5, 82.4, 80.4, 78.2, 77.7, 75.0, 74.8,
74.6, 74.5, 74.3, 74.1, 74.0, 73.4, 73.9, 70.8, 68.4, 68.4, 68.0, 67.5,
65.7, 61.2, 61.1, 57.5, 57.3, 57.0, 54.7, 18.8, 18.4, 14.2, 14.1 ppm;
HRMS (ESI-QTOF MS): calcd for C91H104Cl12N4O29K: 2175.2686
[M+K]+ , found: 2175.2556.
Tetrasaccharide 13: Zn/Cu (prepared from 500 mg of Zn) was
added to a solution of 12 (200 mg, 0.09 mmol) in AcOH (2 mL),
and the mixture was stirred at room temperature for 30 min. The
insoluble materials were filtered off, and the filtrate was concen-
trated in vacuo. The residual solvent was removed by coevapora-
tion with toluene (10 mL). The residue was dissolved in pyridine
(2 mL) and acetic anhydride (2 mL), and the solution was stirred at
room temperature for 1 h. The reagents were removed by concen-
tration with toluene (10 mL). The residue was purified by silica gel
chromatography (50 g, CHCl3/acetone 9:1) to give 2-N-acetyl tetra-
saccharide as a white solid (93 mg, 62 %). 1H NMR (CDCl3,
400 MHz): d= 7.44–7.21 (m, 31 H), 6.98 (m, 1 H), 6.74 (d, J = 6.8 Hz,
1 H), 6.07 (d, J = 8.4 Hz, 1 H), 5.81 (m, 1 H), 5.47 (s, 1 H), 5.24–5.14
(m, 3 H), 4.95 (d, J = 12.8 Hz, 1 H), 4.84 (d, J = 3.6 Hz, 1 H), 4.74–4.64
(m, 5 H), 4.55–4.45 (m, 5 H), 4.36–4.02 (m, 14 H), 3.96–3.38 (m, 20 H),
3.23 (t, J = 9.6 Hz, 1 H), 3.13 (m, 1 H), 3.05 (m, 1 H), 1.98 (s, 3 H), 1.94
(s, 3 H), 1.88 (s, 3 H), 1.78 (s, 3 H), 1.37 (d, J = 6.8 Hz, 3 H), 1.31–
1.21 ppm (m, 9 H); 13C NMR (CDCl3, 125 MHz): d= 175.9, 174.7,
172.4, 172.3, 171.8, 169.8, 139.6, 138.8, 138.3, 138.1, 138.1, 138.0,
137.2, 133.7, 129.1, 128.5, 128.3, 128.3, 128.2, 128.2, 128.0, 127.9,
127.8, 127.7, 127.4, 127.3, 127.2, 125.9, 117.5, 102.4, 101.1, 100.8,
100.5, 96.3, 95.5, 82.6, 80.3, 76.4, 75.8, 75.4, 74.9, 74.6, 74.1, 73.8,
73. 4, 73.4, 73.2, 72.8, 71.1, 68.5, 68.5, 68.2, 68.0, 65.9, 61.3, 61.0,
55.4, 55.0, 53.4, 52.1, 29.7, 29.3, 23.9, 23.6, 23.5, 23.4, 23.1, 18.8,
18.6, 14.2, 14.1 ppm; HRMS (ESI-QTOF MS): calcd for
C87H108N4O25Na: 1631.7200 [M+Na]
+ , found: 1631.7169.
LiOH (16 mg, 0.7 mmol) was added to a solution of 2-N-acetyl tet-
rasaccharide (93 mg, 0.06 mmol) in dioxane/THF/H2O (2:4:1,
 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim ChemBioChem 2013, 14, 482 – 488 486
CHEMBIOCHEM
FULL PAPERS www.chembiochem.org
4.0 mL), and the mixture was stirred at room temperature for 1 h.
The solution was neutralized with Dowex H+ (Dowex 50W  8,
200–400 mesh H form, Dow Chemicals), then applied to an HP-20
column (2 cm  10 cm). Organic and inorganic salts were removed
by elution with H2O (160 mL), followed by elution with MeOH and
concentration in vacuo to give a tetrasaccharide with a free lactic
acid moiety, 13, as a white solid (89 mg, quant). 1H NMR (CD3OD,
400 MHz): d= 7.34–6.99 (m, 30 H), 5.83 (m, 1 H), 5.40 (s, 1 H), 5.20
(dd, J = 17.6, 1.6 Hz, 1 H), 5.09–5.00 (m, 2 H), 4.84 (d, J = 11.2 Hz,
1 H), 4.68 (d, J = 3.6 Hz, 1 H), 4.60–4.37 (m, 8 H), 4,25–4.21 (m, 3 H),
4.09–4.00 (m, 2 H), 3.95–3.31 (m, 22 H), 3.04–2.95 (m, 2 H), 1.89 (m,
6 H), 1.77 (s, 6 H), 1.31–1.19 ppm (m, 6 H); HRMS (ESI-QTOF MS):
calcd for C83H100N4O25Na: 1575.6574 [M+Na]
+ , found: 1575.6508.
Tetrasaccharide dipeptide backbone 14: WSCD·HCl (8 mg,
0.048 mmol) and triethylamine (15 mL, 0.096 mmol) were added at
0 8C to a solution of 13 (25 mg, 0.016 mmol), HCl·l-Ala-d-isoGln-
OBn (22 mg, 0.064 mmol), and HOBt (7 mg, 0.048 mmol) in DMF
(3 mL), and the mixture was stirred at RT overnight. The mixture
was concentrated, and the residue was dissolved in CHCl3. The so-
lution was washed with citric acid (1 m, 20 mL), H2O (20 mL), sat.
aq. NaHCO3 (20 mL), and brine (20 mL). The organic layer was dried
over Na2SO4, and concentrated in vacuo. The residue was purified
by silica gel chromatography (5 g, CHCl3/MeOH 15:1) to give 14 as
a white solid (28 mg, 82 %). 1H NMR ([D7]DMF, 400 MHz): d= 8.12–
8.04 (m, 3 H), 7.85 (d, J = 9.2 Hz, 1 H), 7.68–7.00 (m, 48 H), 5.90 (m,
1 H), 5.70 (s, 1 H), 5.14 (dd, J = 17.2, 1.9 Hz, 1 H), 5.08–5.17 (m, 6 H),
4.95 (d, J = 11.2 Hz, 1 H), 4.84 (d, J = 8.4 Hz, 1 H), 4.76 (d, J = 3.7 Hz,
1 H), 4.64–4.29 (m, 15 H), 4.20–3.57 (m, 24 H), 3.25–3.15 (m, 3 H),
2.49 (t, J = 8.0 Hz, 4 H), 2.31–2.20 (m, 2 H), 1.86–1.77 (m, 14 H), 1.29–
1.20 ppm (m, 12 H); 13C NMR ([D7]DMF, 100 MHz): d= 173.9, 173.9,
173.3, 173.2, 173.1, 173.0, 170.8, 170.8, 170.1, 140.7, 140.4, 139.8,
139.7, 139.6, 138.7, 137.3, 137.3, 135.3, 129.4, 129.1, 128.9, 128.7,
128.6, 138.5, 128.2, 128.2, 128.1, 128.0, 127.9, 127.8, 127.4, 126,7,
116,9, 101.8, 101.3, 97.5, 92.9, 81.6, 80.2, 80.0, 79.8, 79.6, 77.2, 75.3,
74.5, 73.0, 72.9, 71.0, 69.2, 68.8, 68.5, 66.7, 66.3, 53.3, 52.8, 50.0,
49.6, 36.0, 31.0, 28.0, 23.7, 23.6, 23.4, 22.8, 19.4, 19.2, 18.3,
17.7 ppm; HRMS (ESI-QTOF MS): calcd for C113H138N10O31Na2 :
1088.4662 [M+2 Na]2 + , found: 1088.4655.
Tetrasaccharide tetrapeptide backbone 16: HATU (11 mg,
0.019 mmol) and triethylamine (8 mL, 0.039 mmol) were added at
0 8C to a solution of 13 (15 mg, 0.006 mmol) and HCl·l-Ala-d-
isoGln-l-Lys(Z)-d-Ala-OBn (19 mg, 0.019 mmol) in DMF (3 mL), and
the mixture was stirred at RT overnight. The mixture was concen-
trated, and the residue was dissolved in CHCl3. The solution was
washed with citric acid (1 m, 20 mL), H2O (20 mL), sat. aq. NaHCO3
(20 mL), and brine (20 mL). The organic layer was dried over
Na2SO4 and concentrated in vacuo. The residue was purified by
silica gel chromatography (5 g, CHCl3/MeOH 15:1) to give 16 as
a white solid (23 mg, 81 %). 1H NMR (CDCl3/CD3OD 4:1, 500 MHz):
d= 7.41–7.21 (m, 50 H), 5.85 (m, 1 H), 5.43 (s, 1 H), 5.25–5.06 (m,
8 H), 4.93–4.81 (m, 2 H), 4.68–4.25 (m, 16 H), 4.13–3.89 (m, 11 H),
3.47–3.36 (m, 11 H), 3.12 (m, 4 H), 2.35–2.18 (m, 6 H), 2.02–1.79 (m,
14 H), 1.48–1.10 ppm (m, 30 H); HRMS (ESI-QTOF MS): calcd for
C147H184N16O39Na2 : 1421.6351 [M+2 Na]
2 + , found: 1421.6357.
Deprotection of the tetrasaccharide dipeptide 1 b: Palladium hy-
droxide (55 mg) in AcOH was added to a solution of 14 (28 mg,
0.013 mmol) in AcOH (1 mL), and the mixture was stirred under H2
(2 MPa) for one day. The reaction was monitored by TLC, and the
hydrogenolysis was continued until deprotection was complete.
The Pd catalyst was filtered off by using celite, and the filtrate was
concentrated. The residue was lyophilized from acetonitrile/H2O to
give 1 b (16.6 mg, 89 %) as a white solid. 1H NMR (CD3OD,
500 MHz): d= 4.81–4.25 (m, 9 H), 3.87–3.29 (m, 26 H), 2.38 (br s, 4 H),
2.19 (br s, 2 H), 1.97 (m, 14 H), 1.60–1.58 (m, 2 H), 1.43–1.34 (m,
12 H), 0.95–0.91 ppm (dd, J = 12.0, 7.0 Hz, 3 H); 13C NMR (CD3OD,
125 MHz): d= 176.3, 175.9, 175.6, 175.2, 175.2, 173.9, 173.9, 173.8,
173.5, 103.3, 103.1, 101.8, 98.2, 83.4, 81.9, 81.6, 80.0, 78.7, 78.4,
78.0, 77.4, 76.8, 76.0, 73.9, 72.2, 71.2, 70.9, 70.8, 62.5, 62.0, 61.6,
61.4, 57.0, 56.4, 55.9, 55.1, 53.9, 53.8, 50.7, 49.6, 31.6, 28.8, 28.4,
23.7, 23.4, 22.5, 19.5, 18.9, 17.7, 17.5, 11.0 ppm; HRMS (ESI-QTOF
MS): calcd for C57H94N10O31Na: 1437.5984 [M+Na]
+ , found:
1437.6008.
1 c–1 g were similarly synthesized. 1 c : 1H NMR (D2O, 500 MHz): d=
5.11 (d, J = 2.6 Hz, 1 H), 4.49 (d, J = 8.5 Hz, 1 H), 4.27 (dd, J = 9.5,
4.5 Hz, 1 H), 4.22–4.13 (m, 2 H), 3.87–3.44 (m, 14 H), 3.32–3.26 (m,
3 H), 2.47–2.32 (m, 2 H), 2.15–1.88 (m, 8 H), 1.36–1.29 (m, 7 H), 1.11–
1.00 ppm (m, 5 H); 13C NMR (D2O, 150 MHz): d= 178.9, 175.9, 175.6,
175.1, 174.5, 174.2, 174.0, 101.3, 94.8, 90.4, 82.5, 79.7, 78.2, 75.6,
78.2, 75.6, 74.6, 72.5, 70.0, 69.3, 68.7, 61.3, 60.6, 60.1, 54.9, 53.6,
49.7, 39.3, 31.9, 31.1, 27.0, 26.3, 27.0, 26.3, 22.2, 22.1, 21.9, 18.8,
16.6 ppm; HRMS (ESI-QTOF): calcd for C33H57N7O17Na: 846.3709
[M+Na]+ , found: 846.3697.
1 d : 1H NMR (D2O, 400 MHz): d= 4.40–4.35 (m, 2 H), 4.26 (m, 1 H),
4.10–4.03 (m, 5 H), 3.79–3.20 (m, 29 H), 2.84 (t, J = 7.0 Hz, 4 H), 2.26–
2.24 (m, 4 H), 2.07–2.03 (m, 2 H), 1.90–1.80 (m, 14 H), 1.66 (m, 2 H),
1.58–1.51 (m, 6 H), 1.43–1.39 (m, 2 H), 1.31–1.21 (m, 16 H), 0.74 ppm
(t, J = 7.4 Hz, 3 H); HRMS (ESI-QTOF MS): calcd for C69H119N14O33K:
855.3851 [M+H+K]2 + , found: 855.3832.
1 e: 1H NMR (D2O, 500 MHz): d= 5.06 (d, J = 3.0 Hz, 1 H), 4.44 (d, J =
8.0 Hz, 1 H), 4.20–4.02 (m, 5 H), 3.82–3.38 (m, 12 H), 2.86 (t, J =
7.5 Hz, 2 H), 2.31–2.28 (m, 2 H), 2.04 (m, 1 H), 1.91 (s, 3 H), 1.86–1.82
(m, 4 H), 1.74–1.62 (m, 4 H), 1.32–1.30 (m, 5 H), 1.25 (d, J = 6.3 Hz,
3 H), 1.19 ppm (d, J = 7.3 Hz, 3 H); HRMS (ESI-QTOF): calcd for
C36H63N8O18: 895.4260 [M+H]
+ , found: 895.4213.
1 f : 1H NMR (D2O, 400 MHz): d= 4.39–4.37 (m, 3 H), 4.25–4.22 (m,
2 H), 4.17–4.10 (m, 8 H), 3.76–3.15 (m, 26 H), 2.85 (t, J = 7.2 Hz, 4 H),
2.28–2.26 (m, 4 H), 2.07–2.03 (m, 2 H), 1.90–1.80 (m, 14 H), 1.63–1.52
(m, 10 H), 1.44–1.42 (m, 2 H), 1.31–1.17 (m, 20 H), 0.74 (t, J = 7.4 Hz,
3 H); HRMS (ESI-QTOF MS): calcd for C75H129N16O35Na: 918.4352
[M+H+Na]2 + , found: 918.4310.
1 g : 1H NMR (D2O, 400 MHz): d= 4.43–4.38 (m, 2 H), 4.30–4.06 (m,
11 H), 3.88–3.25 (m, 28 H), 2.87 (t, J = 7.6 Hz, 4 H), 2.29–2.26 (m, 4 H),
2.09–2.01 (m, 2 H), 1.92–1.82 (m, 14 H), 1.67–1.53 (m, 8 H), 1.48–1.41
(m, 2 H), 1.33–1.24 (m, 28 H), 0.77 (t, J = 7.6 Hz, 3 H); HRMS (ESI-
QTOF MS): calcd for C81H140N18O37: 978.4813 [M+2 H]
2 + , found:
978.4783.
HEK293T bioassay for human Nod2 activity: Ligand-dependent
NF-kB activation was determined by using 0.5  105 HEK293T cells
transfected with expression plasmids of Nod2 (33 ng of pMX2-
HANod2) in the presence of reporter plasmids, NF-kB-dependent
pBxIV-luc, and control pEF1BOS-b-Gal, as described.[3] Briefly,
HEK293T cells were transfected with expression plasmids by the
calcium phosphate method. Eight hours post-transfection, the cells
were treated with medium containing a synthesized ligand.
24 hours post-transfection, ligand-dependent NF-kB activation was
determined by using a luciferase reporter assay.[18]
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